

Current Trial Highlights

CC#23722: Wearable Activity Tracking to Curb Hospitalizations (WATCH) **PI: Julian Hong**

CC#194522 RT-DT : Phase II Trial of Durvalumab (MEDI4736) with/without Tremelimumab for Advanced Hepatocellular Carcinoma after Palliative Hypofractionated Radiotherapy **PI: Mary Feng**

Other Enrolling Clinical Trials

CC#239814: An Evaluation of Changes in the Relationships Between Fatigue and Molecular Mechanisms in Cancer Patients Receiving Curative-Intent Combined Chemotherapy and Radiation Therapy (CCRT) **PI: Sue Yom**

CC#24721: An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC) (PSMA-DC) **PI: Steven Seyedin**

CC#24726: Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma (NPC) **PI: Sue Yom**

Tumor-informed ctDNA testing for minimal residual disease monitoring following curative-intent treatment of squamous cell carcinoma of the head and neck (CtDNA) **PI: Jason Chan**

CC#23721: Two-fraction High Dose Rate Brachytherapy as Monotherapy Delivered Three Hours Apart in Localized Prostate Cancer: A Pilot Study **PI: I-Chow “Joe” Hsu**

NRG-BN012: A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Reselectable Brain Metastases **PI: Steve Braunstein**

NRG HN006: Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer **PI: Jason Chan**

CC#21721: Optimization of MRI for Liver Radiotherapy **PI: Mary Feng**

CC#19721 : Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI) **PI: Mary Feng**

RTOG 1216: Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck **PI: Jason Chan**

NRG-GU008: Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy **PI: Steven Seyedin**

NRG- GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (Predict-RT) *Prostate RNA Expression/Decipher To Individualize Concurrent Therapy with Radiation **PI: Steven Seyedin**

NRG-GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (Guidance) **PI: Steven Seyedin**

NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (Samurai)
PI: Steven Seyedin

CC#22721: Addressing taste dysfunction with miraculin in head and neck cancer patients receiving radiation therapy: A double-blinded, placebo-controlled, randomized phase III trial **PI: Sue Yom**

CC#21728: Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR trial **PI: Sue Yom**



RTOG 3521: TRANSPARENT: Single-Arm Study of Toripalimab in Combination with Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naïve Participants **PI: Sue Yom**

CC#24724: A Pilot trial of adjuvant hypofractionated stereotactic radiosurgery for intermediate-risk meningioma (SRS-AIM) **PI: William Chen**